

L Kristin Newby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5456118/publications.pdf>

Version: 2024-02-01

135
papers

19,610
citations

66343

42
h-index

18647

119
g-index

137
all docs

137
docs citations

137
times ranked

22482
citing authors

#	ARTICLE	IF	CITATIONS
1	A new biomarker of acute coronary ischaemia: from bench to bedside?. <i>European Heart Journal</i> , 2022, 43, 164-166.	2.2	3
2	End-of-life care in the cardiac intensive care unit: a contemporary view from the Critical Care Cardiology Trials Network (CCCTN) Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 190-197.	1.0	11
3	OUP accepted manuscript. <i>journal of applied laboratory medicine</i> , The, 2022, , .	1.3	0
4	SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 627-634.	4.8	8
5	Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	5
6	Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME study). <i>Journal of Diabetes Investigation</i> , 2021, 12, 200-206.	2.4	14
7	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non-ST-Segment Elevation Myocardial Infarction for Intensive Care Unit Admission. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007602.	2.2	4
8	Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2021, 354, 577541.	2.3	6
9	Survival in Patients with Non-Ischemic Cardiomyopathy with Preserved versus Reduced Ejection Fraction. <i>CJC Open</i> , 2021, 3, 1333-1340.	1.5	2
10	Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm. <i>Circulation</i> , 2021, 144, 773-787.	1.6	25
11	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. <i>Critical Pathways in Cardiology</i> , 2021, Publish Ahead of Print, 173-178.	0.5	0
12	Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA). <i>Molecular Genetics and Metabolism Reports</i> , 2020, 25, 100651.	1.1	1
13	In HF with LVEF \geq 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. <i>Annals of Internal Medicine</i> , 2020, 172, JC65.	3.9	0
14	In older patients with NSTEMI-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year. <i>Annals of Internal Medicine</i> , 2020, 173, JC28.	3.9	0
15	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.	10.9	38
16	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. <i>American Heart Journal</i> , 2020, 225, 3-9.	2.7	12
17	Near Real Time EHR Data Utilization in a Clinical Study. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 337-341.	0.3	1
18	Age-Related Adverse Inflammatory and Metabolic Changes Begin Early in Adulthood. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 283-289.	3.6	15

#	ARTICLE	IF	CITATIONS
19	Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury. <i>Circulation</i> , 2019, 140, 1661-1678.	1.6	207
20	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. <i>Circulation: Heart Failure</i> , 2019, 12, e006635.	3.9	58
21	A Proposal for Modest Revision of the Definition of Type 1 and Type 2 Myocardial Infarction. <i>Circulation</i> , 2019, 140, 1773-1775.	1.6	35
22	High-Sensitivity Troponin in Acute Heart Failure Triage. <i>Circulation: Heart Failure</i> , 2019, 12, e006241.	3.9	1
23	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	5.2	80
24	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	2.8	403
25	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	2.7	7
26	Response by McCord et al to Letter Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation High-Sensitivity Cardiac Troponin Assays to Diagnose Myocardial Infarction." <i>Circulation</i> , 2019, 139, 564-565.	1.6	0
27	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1059-1077.	2.8	103
28	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. <i>American Heart Journal</i> , 2019, 211, 54-59.	2.7	9
29	Inflammation as a Treatment Target after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2562-2563.	27.0	34
30	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022.	2.8	54
31	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	2.2	23
32	Systematic review and directors survey of quality indicators for the cardiovascular intensive care unit. <i>International Journal of Cardiology</i> , 2018, 260, 219-225.	1.7	7
33	Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. <i>American Heart Journal</i> , 2018, 201, 103-110.	2.7	3
34	Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. <i>American Heart Journal</i> , 2018, 199, 150-155.	2.7	2
35	A "shocking" new code status. <i>American Heart Journal</i> , 2018, 198, 1-3.	2.7	1
36	High-Sensitivity Troponin in Noncardiac Surgery. <i>Circulation</i> , 2018, 137, 1233-1235.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Provocative biomarker stress test: stress-delta N-terminal pro-B type natriuretic peptide. <i>Open Heart</i> , 2018, 5, e000847.	2.3	5
38	The Impact of Multiple Dimensions of Socioeconomic Status on Physical Functioning Across the Life Course. <i>Gerontology and Geriatric Medicine</i> , 2018, 4, 233372141879402.	1.5	5
39	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	2.2	28
40	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Nonâ€“STâ€“Segmentâ€“Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	26
41	Implementation of a Regional Network for STâ€“Segmentâ€“Elevation Myocardial Infarction (STEMI) Care and 30â€“Day Mortality in a Lowâ€“to Middleâ€“Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	26
42	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneousâ€“Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	2.9	25
43	Implications of High-Sensitivity Troponinâ€“Testing. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2625-2627.	2.8	4
44	The high cost of critical care unit over-utilization for patients with NSTEMI ACS. <i>American Heart Journal</i> , 2018, 202, 84-88.	2.7	19
45	Physical Performance Across the Adult Life Span: Correlates With Age and Physical Activity. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw120.	3.6	55
46	Relationship Between Peak Troponin Values and Longâ€“Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
47	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017, 130, 1170-1176.	1.5	8
48	Sex, Region, and Outcomes After Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	2
49	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017, 190, 135-139.	2.7	26
50	Reconciling Systems for Acute Myocardial Infarction Definition and Coding Classification. <i>Clinical Chemistry</i> , 2017, 63, 24-26.	3.2	0
51	Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	23
52	To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	1
53	Failure to Launch. <i>JACC Basic To Translational Science</i> , 2017, 2, 484-497.	4.1	44
54	In-hospital cardiac arrest: Complex clinical challenges in need of unique solutions. <i>American Heart Journal</i> , 2017, 193, 104-107.	2.7	0

#	ARTICLE	IF	CITATIONS
55	Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, e003864.	2.2	36
56	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 36.	6.1	31
57	Myocardial Ischemia on Exercise Stress Echocardiography Testing Is Not Associated with Changes in Troponin T Concentrations. <i>Journal of Applied Laboratory Medicine</i> , 2017, 1, 532-543.	1.3	7
58	It Happened While You Were Sleeping. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	0
59	Intravenous Beta-Blockers for Cardioprotection in STEMI. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2716-2718.	2.8	5
60	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573.	1.6	17
61	The Genesis, Maturation, and Future of Critical Care Cardiology. <i>Journal of the American College of Cardiology</i> , 2016, 68, 67-79.	2.8	85
62	Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 376-385.	2.1	13
63	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	2.7	11
64	Association of standard clinical and laboratory variables with red blood cell distribution width. <i>American Heart Journal</i> , 2016, 174, 22-28.	2.7	10
65	Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?. <i>American Heart Journal</i> , 2016, 175, 184-192.	2.7	31
66	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 389-397.	2.4	14
67	Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry. <i>European Heart Journal</i> , 2016, 37, 161-163.	2.2	1
68	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. <i>International Journal of Cardiology</i> , 2016, 203, 708-713.	1.7	5
69	Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2016, 31, 106-14.	0.6	3
70	Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a High-Risk Population. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	1
71	Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4279.	4.3	7
72	Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0132259.	2.5	23

#	ARTICLE	IF	CITATIONS
73	Simultaneous Consideration of Multiple Candidate Protein Biomarkers for Long-Term Risk for Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 168-177.	5.1	17
74	Back to the Future. <i>Circulation</i> , 2015, 131, 1234-1235.	1.6	3
75	Impact of Exercise Stress Testing on Diagnostic Gene Expression in Patients With Obstructive and Nonobstructive Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2015, 115, 1346-1350.	1.6	0
76	Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices systematic review. <i>Clinical Biochemistry</i> , 2015, 48, 204-212.	1.9	20
77	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 357-367.	2.2	30
78	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. <i>Journal of the American Heart Association</i> , 2015, 4, e001573.	3.7	20
79	Troponin testing risk stratification to stratified medicine. <i>Nature Reviews Cardiology</i> , 2015, 12, 625-626.	13.7	4
80	Does This Patient With Chest Pain Have Acute Coronary Syndrome?. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1955.	7.4	170
81	A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 449-457.	2.4	64
82	Understanding Population Cardiovascular Health. <i>Circulation</i> , 2015, 132, 1303-1304.	1.6	5
83	Applying the Evidence in Coronary Disease Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 547-548.	2.8	2
84	A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial. , 2014, 10, 760-768.e1.		17
85	High-Sensitivity Troponin Assays: Evidence, Indications, and Reasonable Use. <i>Journal of the American Heart Association</i> , 2014, 3, e000403.	3.7	108
86	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. <i>Lancet, The</i> , 2014, 384, 1187-1195.	13.7	123
87	Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. <i>Atherosclerosis</i> , 2014, 232, 191-196.	0.8	109
88	Improving population representation through geographic health information systems: mapping the MURDOCK study. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 402-12.	0.0	6
89	Aspirin Exposure Reveals Novel Genes Associated With Platelet Function and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1267-1276.	2.8	65
90	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e78-e140.	2.8	2,612

#	ARTICLE	IF	CITATIONS
91	Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. <i>International Journal of Cardiology</i> , 2013, 167, 548-554.	1.7	10
92	Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JACC: Heart Failure</i> , 2013, 1, 223-229.	4.1	48
93	Strategies for Improving Survival After In-Hospital Cardiac Arrest in the United States: 2013 Consensus Recommendations. <i>Circulation</i> , 2013, 127, 1538-1563.	1.6	258
94	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. <i>European Heart Journal</i> , 2013, 34, 894-902.	2.2	21
95	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
96	Myocardial Infarction Rule-out in the Emergency Department: Are High-Sensitivity Troponins the Answer?. <i>Archives of Internal Medicine</i> , 2012, 172, 1218.	3.8	10
97	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	2.2	2,447
98	Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. <i>American Heart Journal</i> , 2012, 163, 844-850.e1.	2.7	271
99	The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale. <i>American Heart Journal</i> , 2012, 164, 646-653.e3.	2.7	24
100	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	2.8	2,558
101	Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2012, 125, 1085-1094.	1.5	40
102	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2427-2463.	2.8	352
103	Metabolic profiles predict adverse events after coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 873-878.	0.8	45
104	Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity. <i>American Heart Journal</i> , 2011, 162, 64-73.	2.7	33
105	Acute coronary syndromes in the elderly. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 220-222.	1.5	13
106	Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update. <i>Circulation</i> , 2011, 123, 1243-1262.	1.6	1,576
107	Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 135-142.	2.2	345
108	Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 207-214.	5.1	390

#	ARTICLE	IF	CITATIONS
109	Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. <i>American Heart Journal</i> , 2010, 160, 371-379.e2.	2.7	33
110	Prognostic Biomarkers in Individuals with Prevalent Coronary Heart Disease. <i>Disease Markers</i> , 2009, 26, 265-271.	1.3	8
111	Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 360, 2176-2190.	27.0	459
112	Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2009, 32, E22-8.	1.8	66
113	Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. <i>American Heart Journal</i> , 2009, 157, 716-723.	2.7	121
114	Clopidogrel use and bleeding after coronary artery bypass graft surgery. <i>American Heart Journal</i> , 2008, 156, 886-892.	2.7	97
115	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 547-551.	3.2	188
116	Long term use of eicosapentaenoic acid reduced major coronary events in hypercholesterolaemia. <i>Evidence-Based Medicine</i> , 2007, 12, 136-136.	0.6	0
117	Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins. <i>Evidence-Based Medicine</i> , 2007, 12, 42-42.	0.6	0
118	Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease. <i>Circulation</i> , 2006, 113, 203-212.	1.6	453
119	Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 47, 312-318.	2.8	67
120	Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1912.	7.4	588
121	The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY) Tj ETQq1 1 0.784314 rgBT front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—Study design and rationale. <i>American Heart Journal</i> , 2005, 149, 994-1002.	2.7	85
122	Elevated plasma natriuretic peptide levels were associated with cardiovascular events. <i>ACP Journal Club</i> , 2004, 141, 50.	0.1	0
123	Elevated plasma natriuretic peptide levels were associated with cardiovascular events. <i>ACP Journal Club</i> , 2004, 141, 50.	0.1	0
124	Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, S31-S36.	2.8	69
125	Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?. <i>European Heart Journal</i> , 2003, 24, 1613-1615.	2.2	5
126	Prognostic significance of elevated troponin i after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1738-1744.	2.8	170

#	ARTICLE	IF	CITATIONS
127	Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2002, 287, 3087.	7.4	136
128	Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin Tâ€“Positive Status. Circulation, 2001, 103, 2891-2896.	1.6	206
129	Cost Effectiveness of Early Discharge after Uncomplicated Acute Myocardial Infarction. New England Journal of Medicine, 2000, 342, 749-755.	27.0	127
130	The Role of Enzymatic Markers in the New Millennium: Point-of-Care Testing and Beyond. Journal of Thrombosis and Thrombolysis, 1998, 5, S113-S118.	2.1	0
131	The Chest-Pain Unit â€” Ready for Prime Time?. New England Journal of Medicine, 1998, 339, 1930-1932.	27.0	24
132	Value of Serial Troponin T Measures for Early and Late Risk Stratification in Patients With Acute Coronary Syndromes. Circulation, 1998, 98, 1853-1859.	1.6	259
133	Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) trial. Journal of the American College of Cardiology, 1996, 27, 625-632.	2.8	117
134	Identifying patient risk: The basis for rational discharge planning after acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 1996, 3, 107-115.	2.1	6
135	Novel Markers in Patients with Suspected Acute Coronary Syndromes. , 0, , 75-92.		0